AP1896A - The method of treating cancer - Google Patents

The method of treating cancer

Info

Publication number
AP1896A
AP1896A APAP/P/2004/003070A AP2004003070A AP1896A AP 1896 A AP1896 A AP 1896A AP 2004003070 A AP2004003070 A AP 2004003070A AP 1896 A AP1896 A AP 1896A
Authority
AP
ARIPO
Prior art keywords
cancer
treating cancer
mycobactcrium
management
useful
Prior art date
Application number
APAP/P/2004/003070A
Other languages
English (en)
Other versions
AP2004003070A0 (en
Inventor
Bakulesh Mafatlal Khamar
Original Assignee
Bakulesh Mafatlal Khamar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bakulesh Mafatlal Khamar filed Critical Bakulesh Mafatlal Khamar
Publication of AP2004003070A0 publication Critical patent/AP2004003070A0/xx
Application granted granted Critical
Publication of AP1896A publication Critical patent/AP1896A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
APAP/P/2004/003070A 2001-12-10 2002-12-10 The method of treating cancer AP1896A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1167MU2001 2001-12-10
PCT/IB2002/005516 WO2003049667A2 (en) 2001-12-10 2002-12-10 The method of treating cancer

Publications (2)

Publication Number Publication Date
AP2004003070A0 AP2004003070A0 (en) 2004-06-30
AP1896A true AP1896A (en) 2008-10-08

Family

ID=11097334

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2004/003070A AP1896A (en) 2001-12-10 2002-12-10 The method of treating cancer

Country Status (9)

Country Link
US (1) US7972609B2 (enExample)
JP (1) JP4527979B2 (enExample)
AP (1) AP1896A (enExample)
AU (1) AU2002348738B2 (enExample)
CA (1) CA2469266C (enExample)
GB (1) GB2389532C (enExample)
NZ (1) NZ533417A (enExample)
UA (1) UA79952C2 (enExample)
WO (1) WO2003049667A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1948782T3 (pl) 2005-04-25 2013-01-31 Cadila Pharmaceuticals Ltd Adiuwanty szczepionki
GB2464231B (en) * 2006-11-23 2010-08-04 Cadila Pharmaceuticals Ltd Poly-TLR antagonist
CA2681420A1 (en) * 2007-03-20 2008-09-25 Cadila Pharmaceuticals Limited P38 inhibitors
WO2009001204A2 (en) * 2007-06-28 2008-12-31 Cadila Pharmaceuticals Ltd. Mitogen activated protein kinase modulator
WO2011083493A1 (en) * 2010-01-08 2011-07-14 National Institute Of Immunology Human chorionic gonadotropin (hcg) based vaccine for prevention and treatment of cancer
US9795659B2 (en) * 2010-02-19 2017-10-24 Cadila Pharmaceuticals, Ltd. Pharmaceutical composition of killed cells with substantially retained immunogenicity
MX340143B (es) * 2010-10-13 2016-06-28 Telesta Therapeutics Ip Inc Composiciones de pared de célula de ácido ribonucléico bacterial y métodos para hacerlas y usarlas.
RU2580888C2 (ru) * 2011-01-11 2016-04-10 Кадила Фармасьютикалз Лимитед Фармацевтическая композиция для лечения рака
TR201101874A2 (tr) * 2011-02-25 2011-08-22 Leyla A�An Nac�Ye Yüzeyel mesane tümorü tedavisinde kullanılabilecek mycobacterıum(mikobakteri) brumae hücre duvarı ekstreleri.
WO2012117323A1 (en) * 2011-02-28 2012-09-07 Cadila Pharmaceuticals Limited Therapeutic cancer vaccine
JP2014521599A (ja) * 2011-07-05 2014-08-28 カディラ ファーマシューティカルズ リミテッド がん抗原
US20200368293A1 (en) * 2018-01-18 2020-11-26 Vedanta Biosciences, Inc. Compositions and methods for the treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869645A (en) * 1997-10-15 1999-02-09 Board Of Trustees Of The University Of Illinois Method for isolating high molecular weight antineoplastic glycans using urea
US6056964A (en) * 1995-03-29 2000-05-02 Stanford Rook Limited Immunotherapeutic agent and its use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504005A (en) * 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US6126945A (en) * 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
IL105503A (en) * 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
GB9223816D0 (en) * 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
US5767156A (en) * 1993-10-06 1998-06-16 Peptide Technology Limited Polyunsaturated fatty acids and uses thereof
US6090385A (en) * 1993-12-10 2000-07-18 Maes; Hubert Method of treating cancer
GB9406301D0 (en) * 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
AUPP437698A0 (en) * 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
WO2003075824A2 (en) * 2002-03-08 2003-09-18 Modi, Rajiv, Indravadan Process of manufacturing pharmaceutical composition useful for management of tuberculosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6056964A (en) * 1995-03-29 2000-05-02 Stanford Rook Limited Immunotherapeutic agent and its use
US5869645A (en) * 1997-10-15 1999-02-09 Board Of Trustees Of The University Of Illinois Method for isolating high molecular weight antineoplastic glycans using urea

Also Published As

Publication number Publication date
GB2389532B (en) 2004-10-27
JP2005528332A (ja) 2005-09-22
US20070259005A1 (en) 2007-11-08
WO2003049667A3 (en) 2003-10-09
GB0322773D0 (en) 2003-10-29
GB2389532C (en) 2005-09-08
CA2469266C (en) 2014-02-11
NZ533417A (en) 2008-04-30
US7972609B2 (en) 2011-07-05
CA2469266A1 (en) 2003-06-19
AP2004003070A0 (en) 2004-06-30
AU2002348738B2 (en) 2007-11-08
GB2389532A (en) 2003-12-17
JP4527979B2 (ja) 2010-08-18
AU2002348738A1 (en) 2003-06-23
WO2003049667A2 (en) 2003-06-19
UA79952C2 (en) 2007-08-10

Similar Documents

Publication Publication Date Title
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
WO2005063297A3 (en) Melatonin combination therapy for improving sleep quality
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
PL312219A1 (en) Application of nona- and decapeptides in obtaining a therapeutic agent for fighting against aids
HRP20040042A2 (en) Substituted oxazolidinones for combinational therapy
ATE331534T1 (de) Anwendung von zielgerichtetem radium 223 für palliative und therapeutische behandlung von knochenkrebs
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
BG105534A (en) 5ht1 means and method for the treatment of migraine
WO2004019884A3 (en) Agents and methods for enhancing bone formation
BR9811780A (pt) Método de aumento de volume ósseo usando agonistas seletivos fp não ocorrendo naturalmente
AP1896A (en) The method of treating cancer
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
NZ507203A (en) Use of dexmedetomidine for ICU sedation
GB0020504D0 (en) Therapeutic method
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
BR0201974A (pt) Composição farmacêutica para tratamento de alterações do sono
TNSN04235A1 (en) Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
JO3446B1 (ar) طريقة لمعالجة الأرق الأولي
PT1076561E (pt) Terapia de combinacao para o tratamento de tumores
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
MD980129A (en) Antiherpetic remedy
IL129267A0 (en) Treatment of urinary incontinence and compositions for use therein
AU8988901A (en) Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) for treating excess of glucocorticoids